Whether Medicare pays for a GLP-1 drug like Wegovy, Zepbound, Ozempic, or Mounjaro depends on why it is prescribed. Medicare Part D is barred by law from covering a drug used solely to lose weight, but it does cover GLP-1s prescribed for certain medical conditions, and a new time-limited program now offers separate access for weight reduction. This guide walks through each scenario and what you would pay.
The rule that decides everything: why is it prescribed?
The starting point is a statutory one. Medicare Part D is prohibited by law from covering a drug when it is used solely for weight loss, meaning to reduce excess body weight or to maintain weight reduction. That prohibition applies to GLP-1 drugs the same way it applies to any other agent used for weight loss alone.
The same drug, however, can be covered when it treats a recognized medical condition. A GLP-1 prescribed for a use that Part D can cover is handled under your Part D drug plan, subject to the plan's formulary, prior-authorization rules, and cost-sharing.
When Part D covers a GLP-1: the medical indications
A GLP-1 prescribed for a Part-D-coverable medical use is covered by your Part D plan, the same as any other covered drug. Coverable uses include the following.
- Type 2 diabetes. A GLP-1 prescribed to treat Type 2 diabetes is covered under your Part D diabetes coverage, subject to your plan's rules.
- Obstructive sleep apnea (OSA). For example, Zepbound for moderate-to-severe OSA in adults who have obesity.
- Reducing the risk of major adverse cardiovascular events. For example, Wegovy in adults with established cardiovascular disease who also have obesity or overweight.
- Noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis).
In each of these cases, you get the drug through your Part D plan, and normal plan formularies, prior authorization, and cost-sharing apply. A GLP-1 prescribed for one of these indications goes through regular Part D, not the Bridge described below.
How Medicare handles each scenario
The table below distinguishes the common scenarios. The pathway, and the cost, depends on the reason the drug is prescribed.
| Reason the GLP-1 is prescribed | How Medicare handles it |
|---|---|
| Weight loss only | Not covered under regular Part D. May be available through the Medicare GLP-1 Bridge at $50 per monthly supply (temporary; July 1, 2026 to Dec. 31, 2027) |
| Type 2 diabetes | Covered under regular Part D, subject to plan rules and cost-sharing |
| Cardiovascular risk, with established CV disease plus obesity or overweight | Covered under regular Part D (for example, Wegovy) |
| Obstructive sleep apnea, with obesity | Covered under regular Part D (for example, Zepbound) |
| Noncirrhotic MASH | Covered under regular Part D |
The Medicare GLP-1 Bridge
For the weight-reduction use that Part D otherwise excludes, CMS has created the Medicare GLP-1 Bridge, a time-limited demonstration. It gives eligible Medicare Part D beneficiaries access to certain GLP-1 drugs for weight reduction between July 1, 2026 and December 31, 2027.
The key terms are these.
- Cost. The copay is $50 for a monthly supply.
- No deductible. The drugs are furnished outside the Part D benefit payment flow, so the Part D deductible does not apply and the cost does not count toward your Part D phases.
- No sign-up. Beneficiaries do not need to register or opt in.
- It is temporary. The demonstration ends December 31, 2027.
The drugs included in the Bridge for weight reduction are Foundayo, Wegovy (injection and tablets), and Zepbound (the KwikPen formulation only). The single-dose vial and single-dose pen formulations of Zepbound are not included. The drug list was last updated April 6, 2026.
This is a fast-moving area of policy, and the Bridge is a temporary demonstration. Confirm the current status, your eligibility, and which formulations are included with Medicare or your Part D plan before you rely on it. For broader context on coverage limits, see what Medicare doesn't cover.
Frequently asked questions
Not under regular Part D. By law, Part D cannot cover a drug used solely for weight loss. A GLP-1 such as Wegovy can be covered under Part D when it is prescribed for a covered medical condition, for example reducing cardiovascular risk in adults with established cardiovascular disease who also have obesity or overweight. Separately, the Medicare GLP-1 Bridge offers Wegovy for weight reduction at $50 a month through December 31, 2027.
The Medicare GLP-1 Bridge is a time-limited CMS demonstration that gives eligible Medicare Part D beneficiaries access to certain GLP-1 drugs for weight reduction from July 1, 2026 through December 31, 2027. The copay is $50 for a monthly supply. Because the drugs are furnished outside the Part D benefit payment flow, the Part D deductible does not apply. You do not need to register or opt in.
Yes, subject to your plan's rules. A GLP-1 prescribed to treat Type 2 diabetes is a Part-D-coverable use, so your Part D plan covers it under its formulary, prior-authorization, and cost-sharing rules. This is regular Part D coverage, not the Bridge.
For weight reduction, the Bridge includes Foundayo, Wegovy (injection and tablets), and Zepbound in the KwikPen formulation only. The single-dose vial and single-dose pen formulations of Zepbound are not included. The drug list was last updated April 6, 2026, so confirm the current list with Medicare or your plan.
Learn More
- What is Medicare? Parts A, B, C, and D explained
- How Medicare Part D drug coverage works
- What Medicare covers for diabetes
- What Medicare doesn't cover
Find personalized help understanding your Medicare GLP-1 coverage at brevy.com.
The information on Brevy.com is for educational purposes only and is not a substitute for professional legal, financial, or medical advice. Rules vary by state and program and change frequently. Always verify with the relevant agency or a qualified professional. Brevy is not a law firm, financial advisor, or healthcare provider.